uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 3,000 Shares

Key Points

• Christian Klemt, CFO of uniQure, sold 3,000 shares at an average price of $40.04, totaling $120,120, which reduced his holdings by 1.36% to 217,730 shares valued at approximately $8.72 million.
• After recent trades, the stock price of uniQure (NASDAQ:QURE) reached $54.31, with a twelve-month high of $55.11, while the company reported a negative EPS of ($0.69) for the last quarter, surpassing analyst estimates.
• Analysts are optimistic about the stock, with target price upgrades from various firms, including Stifel Nicolaus raising it from $30.00 to $65.00 and UBS Group setting a target of $95.00, indicating a general consensus rating of "Buy."

uniQure N.V. (NASDAQ:QURE - Get Free Report) CFO Christian Klemt sold 3,000 shares of the company's stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $40.04, for a total transaction of $120,120.00. Following the sale, the chief financial officer directly owned 217,730 shares of the company's stock, valued at $8,717,909.20. The trade was a 1.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Christian Klemt also recently made the following trade(s):

• On Friday, September 26th, Christian Klemt sold 15,000 shares of uniQure stock. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00.

uniQure Price Performance

QURE traded up $1.66 on Friday, reaching $54.31. 11,290,994 shares of the company's stock were exchanged, compared to its average volume of 5,557,321. uniQure N.V. has a twelve month low of $4.45 and a twelve month high of $55.11. The stock has a market cap of $2.98 billion, a PE ratio of -13.85 and a beta of 0.14. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The stock's fifty day moving average price is $17.44 and its 200-day moving average price is $14.89.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. The company had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. Sell-side analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Wall Street Analyst Weigh In

QURE has been the subject of several analyst reports. Stifel Nicolaus upped their target price on uniQure from $30.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday. Royal Bank Of Canada reissued an "outperform" rating on shares of uniQure in a research report on Wednesday. The Goldman Sachs Group raised their price objective on shares of uniQure from $13.00 to $56.00 and gave the stock a "neutral" rating in a research report on Thursday. Cantor Fitzgerald boosted their target price on shares of uniQure from $47.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday. Finally, UBS Group set a $95.00 price target on shares of uniQure in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, uniQure presently has an average rating of "Buy" and a consensus target price of $67.17.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its stake in uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock worth $99,000 after buying an additional 5,538 shares during the period. Mraz Amerine & Associates Inc. acquired a new position in shares of uniQure in the 1st quarter worth approximately $106,000. KLP Kapitalforvaltning AS purchased a new position in shares of uniQure during the 2nd quarter worth approximately $117,000. Teacher Retirement System of Texas acquired a new stake in uniQure in the 2nd quarter valued at approximately $151,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in uniQure in the first quarter valued at approximately $152,000. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.